RNA-targeting small molecules

Ipsen’s $18bn Pipeline Expansion Targets Movement Disorders

🔬 Ipsen SA and Skyhawk Therapeutics Inc join forces in a groundbreaking $1.8bn deal to treat rare neurological disorders. 💪🧠